STOCK TITAN

GSK Plc - GSK STOCK NEWS

Welcome to our dedicated news page for GSK Plc (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GSK Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GSK Plc's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
none
-
Rhea-AI Summary
BELLUS Health Inc. announces positive outcome of shareholder vote on acquisition by GSK
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
none
Rhea-AI Summary
BELLUS Health Inc. announces positive outcome of shareholder vote on acquisition by GSK
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
none
-
Rhea-AI Summary
BELLUS Health Inc. announces special meeting for shareholders to consider and adopt a special resolution approving the acquisition of the company by GSK for $14.75 per share. The meeting will be held on June 16, 2023, and shareholders of record as of May 15, 2023, will be eligible to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
acquisition
Rhea-AI Summary
BELLUS Health Inc. announces special meeting for shareholders to consider and adopt a special resolution approving the acquisition of the company by GSK for $14.75 per share. The meeting will be held on June 16, 2023, and shareholders of record as of May 15, 2023, will be eligible to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
acquisition
-
Rhea-AI Summary
BELLUS Health Inc. has announced an agreement to be acquired by GSK for US$14.75 per share of common stock in cash, representing a premium of approximately 103%. The transaction is expected to close in Q3 2023. BELLUS Health is actively advancing its CALM Phase 3 clinical program for camlipixant (BLU-5937) in refractory chronic cough, with topline results expected in the second half of 2024 and 2025. The company is also pursuing the development of its P2X3 receptor pipeline. BELLUS Health reported positive results from its Phase 1 clinical trial for an Extended-Release formulation of camlipixant. The company will be presenting at the upcoming American Thoracic Society 2023 International Conference. Financially, BELLUS Health had available cash, cash equivalents, and short-term investments totaling US$313.0 million as of March 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
Rhea-AI Summary
GSK receives FDA approval for the first RSV vaccine for older adults, AREXVY
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
fda approval
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.62%
Tags
none
GSK Plc

NYSE:GSK

GSK Rankings

GSK Stock Data

87.67B
3.91B
0.05%
14.43%
0.2%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
Brentford

About GSK

GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England.